SNOA Relative Valuation
SNOA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, SNOA is overvalued; if below, it's undervalued.
Historical Valuation
Sonoma Pharmaceuticals Inc (SNOA) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.29 is considered Undervalued compared with the five-year average of -1.15. The fair price of Sonoma Pharmaceuticals Inc (SNOA) is between 13.39 to 15.83 according to relative valuation methord. Compared to the current price of 3.81 USD , Sonoma Pharmaceuticals Inc is Undervalued By 71.56%.
Relative Value
Fair Zone
13.39-15.83
Current Price：3.81
71.56%
Undervalued
-3.91
PE
1Y
3Y
5Y
0.00
EV/EBITDA
Sonoma Pharmaceuticals Inc. (SNOA) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.35. The thresholds are as follows: Strongly Undervalued below -1.11, Undervalued between -1.11 and -0.38, Fairly Valued between 1.07 and -0.38, Overvalued between 1.07 and 1.80, and Strongly Overvalued above 1.80. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-2.03
EV/EBIT
Sonoma Pharmaceuticals Inc. (SNOA) has a current EV/EBIT of -2.03. The 5-year average EV/EBIT is -1.04. The thresholds are as follows: Strongly Undervalued below -5.22, Undervalued between -5.22 and -3.13, Fairly Valued between 1.05 and -3.13, Overvalued between 1.05 and 3.14, and Strongly Overvalued above 3.14. The current Forward EV/EBIT of -2.03 falls within the Historic Trend Line -Fairly Valued range.
0.29
PS
Sonoma Pharmaceuticals Inc. (SNOA) has a current PS of 0.29. The 5-year average PS is 0.27. The thresholds are as follows: Strongly Undervalued below 0.04, Undervalued between 0.04 and 0.16, Fairly Valued between 0.39 and 0.16, Overvalued between 0.39 and 0.50, and Strongly Overvalued above 0.50. The current Forward PS of 0.29 falls within the Historic Trend Line -Fairly Valued range.
12.77
P/OCF
Sonoma Pharmaceuticals Inc. (SNOA) has a current P/OCF of 12.77. The 5-year average P/OCF is 1.35. The thresholds are as follows: Strongly Undervalued below -20.77, Undervalued between -20.77 and -9.71, Fairly Valued between 12.41 and -9.71, Overvalued between 12.41 and 23.46, and Strongly Overvalued above 23.46. The current Forward P/OCF of 12.77 falls within the Overvalued range.
0.00
P/FCF
Sonoma Pharmaceuticals Inc. (SNOA) has a current P/FCF of 0.00. The 5-year average P/FCF is 0.65. The thresholds are as follows: Strongly Undervalued below -0.99, Undervalued between -0.99 and -0.17, Fairly Valued between 1.47 and -0.17, Overvalued between 1.47 and 2.29, and Strongly Overvalued above 2.29. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
Sonoma Pharmaceuticals Inc (SNOA) has a current Price-to-Book (P/B) ratio of 1.59. Compared to its 3-year average P/B ratio of 0.82 , the current P/B ratio is approximately 92.71% higher. Relative to its 5-year average P/B ratio of 1.13, the current P/B ratio is about 39.71% higher. Sonoma Pharmaceuticals Inc (SNOA) has a Forward Free Cash Flow (FCF) yield of approximately -37.87%. Compared to its 3-year average FCF yield of -85.03%, the current FCF yield is approximately -55.46% lower. Relative to its 5-year average FCF yield of -67.95% , the current FCF yield is about -44.26% lower.
1.59
P/B
Median3y
0.82
Median5y
1.13
-37.87
FCF Yield
Median3y
-85.03
Median5y
-67.95
Competitors Valuation Multiple
The average P/S ratio for SNOA's competitors is 3.90, providing a benchmark for relative valuation. Sonoma Pharmaceuticals Inc Corp (SNOA) exhibits a P/S ratio of 0.29, which is -92.54% above the industry average. Given its robust revenue growth of 56.58%, this premium appears sustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of SNOA increased by 40.15% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 3.58M to 5.60M.
The secondary factor is the P/E Change, contributed 27.64%to the performance.
Overall, the performance of SNOA in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
Frequently Asked Questions
Is Sonoma Pharmaceuticals Inc (SNOA) currently overvalued or undervalued?
Sonoma Pharmaceuticals Inc (SNOA) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.29 is considered Undervalued compared with the five-year average of -1.15. The fair price of Sonoma Pharmaceuticals Inc (SNOA) is between 13.39 to 15.83 according to relative valuation methord. Compared to the current price of 3.81 USD , Sonoma Pharmaceuticals Inc is Undervalued By 71.56% .
What is Sonoma Pharmaceuticals Inc (SNOA) fair value?
SNOA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Sonoma Pharmaceuticals Inc (SNOA) is between 13.39 to 15.83 according to relative valuation methord.
How does SNOA's valuation metrics compare to the industry average?
The average P/S ratio for SNOA's competitors is 3.90, providing a benchmark for relative valuation. Sonoma Pharmaceuticals Inc Corp (SNOA) exhibits a P/S ratio of 0.29, which is -92.54% above the industry average. Given its robust revenue growth of 56.58%, this premium appears sustainable.
What is the current P/B ratio for Sonoma Pharmaceuticals Inc (SNOA) as of Jan 08 2026?
As of Jan 08 2026, Sonoma Pharmaceuticals Inc (SNOA) has a P/B ratio of 1.59. This indicates that the market values SNOA at 1.59 times its book value.
What is the current FCF Yield for Sonoma Pharmaceuticals Inc (SNOA) as of Jan 08 2026?
As of Jan 08 2026, Sonoma Pharmaceuticals Inc (SNOA) has a FCF Yield of -37.87%. This means that for every dollar of Sonoma Pharmaceuticals Inc’s market capitalization, the company generates -37.87 cents in free cash flow.
What is the current Forward P/E ratio for Sonoma Pharmaceuticals Inc (SNOA) as of Jan 08 2026?
As of Jan 08 2026, Sonoma Pharmaceuticals Inc (SNOA) has a Forward P/E ratio of -3.91. This means the market is willing to pay $-3.91 for every dollar of Sonoma Pharmaceuticals Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Sonoma Pharmaceuticals Inc (SNOA) as of Jan 08 2026?
As of Jan 08 2026, Sonoma Pharmaceuticals Inc (SNOA) has a Forward P/S ratio of 0.29. This means the market is valuing SNOA at $0.29 for every dollar of expected revenue over the next 12 months.